Chemoattraction of CD34+ progenitor cells and dendritic cells to the site of tumor excision as the first step of an immunotherapeutic approach to target residual tumor cells

Journal of Immunotherapy

Volumn 26, Issue 1, 2003, Pages 31-40

  Banich, James C ^b   Kolesiak, Kristin ^b   Young, M Rita I ^a  

^a HINES VA HOSPITAL   (United States)

^b NONE

Author keywords

CD34+ cells; Chemoattraction; Dendritic cells; Immunotherapy tumor; Vascular endothelial cell growth factor

Indexed keywords

CD11B ANTIGEN; CD34 ANTIGEN; CHEMOATTRACTANT; SODIUM CHLORIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DENDRITIC CELL; ENDOTHELIUM CELL; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ANIMALS; ANTIGENS, CD34; BIOPSY, NEEDLE; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; CHEMOTAXIS; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STEM CELLS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 12244265457     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200301000-00004     Document Type: Article

References (45)

1. Finke J, Ferrone S, Frey A, et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today, 1999; 20:158-60.
2. Heimdal JH, Aarstad HJ, Klementsen B, et al. Peripheral blood mononuclear cell (PBMC) responsiveness in patients with head and neck cancer in relation to tumor stage and prognosis. Acta Otolaryngol 1999;119:281-4.
3. Reichert TE, Day R, Wagner EM, et al. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344-7.
4. + cells within human head and neck squamous cell carcinomas. J Immunol 1997;159:990-6.
5. Kondo Y, Uchino J, Sawaguchi Y, et al. Evaluation of multi skin test in colorectal cancer patients and effects of serum immunosuppressive factor and cytokine production of peripheral mononuclear cells. Am J Clin Oncol 1996;19:159-63.
6. Barrera JL, Verastegui E, Meneses A, et al. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 2000;126:345-51.
7. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18:493-7.
8. Young MRI, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996;67:333-8.
9. + immune suppressive cells in the peripheral blood of patients with head and neck cancer. Annals Otology, Rhinol Laryngol 2000;109:749-54.
10. + cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995;1:95-103.
11. Young MRI, Wright MA, Matthews JP, et al. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-b and nitric oxide. J Immunol 1996;156:1916-22.
12. + T-cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999;162:5728-37.
13. + progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis 1999;17:881-8.
14. + progenitor cells. Human Immunol 2001;62: 332-41.
15. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biologic activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-34.
16. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998;152:1445-52.
17. + hematopoietic progenitor cells. Blood 1996;87:2376-85.
18. + progenitors capable of developing into T cells are not committed to the T cell lineage. J Immunol 1997;158:3571-7.
19. Lodge PA, Jones LA, Bader RA, et al. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 2000;60:829-33.
20. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82.
21. + T cells. J Immunol 1999;163:3597-604.
22. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
23. + cells from the peripheral blood of head and neck cancer patients. J Leuko Biol 1999;65:623-8.
24. + cells to differentiate into antigen presenting dendritic cells. Clin Cancer Res 2001;125:205-12.
25. Baars A, Claessen AM, Wagstaff J, et al. A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 2002;86:1230-4.
26. Karapetis CS, Yip D, Harper PG. The treatment of metastatic colorectal cancer. Int J Clin Pract 1999;53:287-94.
27. 2-producing nonmetastatic Lewis lung carcinoma variants. Cancer Res 1990;50:2973-8.
28. + cells. Int J Cancer 1997;73:663-9.
29. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92:362-7.
30. + fetal liver cells. J Immunol 2001;167:902-9.
31. + hemopoietic cells. Leuk Lymphoma 1996;24:11-25.
32. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275: 964-7.
33. + progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
34. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
35. Abken H, Hombach A, Reinhold U, et al. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol Today 1998;19:2-5.
36. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167:7150-6.
37. + cells from normal bone marrow by Lewis lung carcinoma tumors. Cancer Immunol Immunother 1998;46:253-60.
38. + natural suppressor cells. Int J Cancer 1997;74:69-74.
39. Steube KG, Meyer C, Drexler HG. Secretion of functional hematopoietic growth factors by human carcinoma cell lines. Int J Cancer 1998;78:120-4.
40. Burke F, Relf M, Negus R, et al. A cytokine profile of normal and malignant ovary. Cytokine 1996;8:578-85.
41. Lang SH, Miller WR, Duncan W, et al. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. Int J Cancer 1994;59:235-41.
42. Ohm JE, Shurin MR, Esche C, et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260-8.
43. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-6.
44. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
45. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998; 2:549-58.